Gilead Reduces Prices for Viread® and Truvada® in the Developing World

31-Aug-2005

Gilead Sciences, Inc. announced a significant price reduction for Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) made available through the company's Access Program in the developing world. Both once-a-day antiretroviral medications for HIV are available at no-profit prices in 97 developing countries around the world through this program.

The price decreases announced are due to increased economies of scale, production at a new plant in the Bahamas that manufactures active pharmaceutical ingredient for both Viread and Truvada, and continued improvements in the manufacturing process. As a result of these changes, Viread and Truvada are now priced at US$17.00 and US$26.25 for a 30-day supply, or $0.57 and $0.87 per day, respectively, for private and public programs treating people with HIV/AIDS in the 97 nations of the program. The new prices represent approximately a 31 percent and 12 percent reduction in the no-profit prices for Viread and Truvada, respectively.

Other news from the department research and development

Most read news

More news from our other portals